SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-14-308616
Filing Date
2014-08-13
Accepted
2014-08-13 17:23:21
Documents
11
Period of Report
2014-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q d729064d10q.htm 10-Q 704830
2 EX-31.1 d729064dex311.htm EX-31.1 7624
3 EX-31.2 d729064dex312.htm EX-31.2 7676
4 EX-32.1 d729064dex321.htm EX-32.1 3689
5 EX-32.2 d729064dex322.htm EX-32.2 3741
  Complete submission text file 0001193125-14-308616.txt   5382068

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT rvnc-20140630.xml EX-101.INS 694148
7 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20140630.xsd EX-101.SCH 57665
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rvnc-20140630_cal.xml EX-101.CAL 54090
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvnc-20140630_def.xml EX-101.DEF 234306
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20140630_lab.xml EX-101.LAB 445758
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20140630_pre.xml EX-101.PRE 329828
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36297 | Film No.: 141038559
SIC: 2834 Pharmaceutical Preparations